{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T06:21:36Z","timestamp":1648534896111},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T00:00:00Z","timestamp":1296086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00393-010-0741-y","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T12:35:23Z","timestamp":1295958923000},"page":"375-378","source":"Crossref","is-referenced-by-count":0,"title":["Seltene virale Infektionen unter Immunsuppression"],"prefix":"10.1007","volume":"70","author":[{"given":"T.","family":"Gl\u00fcck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,27]]},"reference":[{"key":"741_CR1","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/art.20351","volume":"50","author":"Korpela","year":"2004","unstructured":"Korpela M, Laasonen L, Hannonen P et al (2004) Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 50:2072\u20132081","journal-title":"Arthritis Rheum"},{"key":"741_CR2","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1002\/art.23141","volume":"56","author":"Heijde","year":"2007","unstructured":"Heijde D van der, Klareskog L, Landew\u00e9 R et al (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56:3928\u20133939","journal-title":"Arthritis Rheum"},{"key":"741_CR3","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"741_CR4","first-page":"1473","volume":"32","author":"Gl\u00fcck","year":"2005","unstructured":"Gl\u00fcck T, Kiefmann B, Grohmann M et al (2005) Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 32:1473\u20131480","journal-title":"J Rheumatol"},{"key":"741_CR5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00040-08","volume":"22","author":"Salvana","year":"2005","unstructured":"Salvana EMT, Salata RA (2005) Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 22:274\u2013290","journal-title":"Clin Microbiol Rev"},{"key":"741_CR6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/11537510-000000000-00000","volume":"33","author":"Berger","year":"2010","unstructured":"Berger JR (2010) Progressive multifocal leukoencephalopathy and newer biological agents. Source Drug Safety 33:969\u2013983","journal-title":"Source Drug Safety"},{"key":"741_CR7","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","volume":"56","author":"Calabrese","year":"2007","unstructured":"Calabrese LH, Molloy ES, Huang D, Ransohoff RM (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 56:2116\u20132128","journal-title":"Arthritis Rheum"},{"key":"741_CR8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","volume":"159","author":"Domm","year":"2008","unstructured":"Domm S, Cinatl J, Mrowietz U (2008) The impact of treatment with tumour necrosis factor-\u03b1 antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 159:1217\u20131228","journal-title":"Br J Dermatol"},{"key":"741_CR9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.0303-6987.2005.00363.x","volume":"32","author":"Shannon","year":"2005","unstructured":"Shannon V, Frambach GE, Seilstad KH et al (2005) Epstein-Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol 32:474\u2013483","journal-title":"J Cutan Pathol"},{"key":"741_CR10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","volume":"65","author":"Calabrese","year":"2006","unstructured":"Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983\u2013989","journal-title":"Ann Rheum Dis"},{"key":"741_CR11","unstructured":"Vassilopoulos D, Calabrese LH (2009) Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 619\u2013625"},{"key":"741_CR12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","volume":"8","author":"Favallia","year":"2009","unstructured":"Favallia EG, Desiatia F, Atzenib F et al (2009) Serious infections during anti-TNF\u03b1 treatment in rheumatoid arthritis patients. Autoimmun Rev 8:266\u2013273","journal-title":"Autoimmun Rev"},{"key":"741_CR13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2008.07.006","volume":"8","author":"Molloy","year":"2008","unstructured":"Molloy ES, Calabrese LH (2008) Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 8:144\u2013146","journal-title":"Autoimmun Rev"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-010-0741-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0741-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:04Z","timestamp":1559061364000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-010-0741-y"}},"subtitle":["Eine \u201enormale\u201c Nebenwirkung?"],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1007\/s00393-010-0741-y","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,27]]}}}